-The Indian Express They are denied entry to temples, given restricted access to water, made to work for a pittance. Now that Orissa's Dalits are asserting themselves against traditions, many are facing ostracism or violent attacks. Debabrata Mohanty reports Until a month before Naveen Patnaik became Orissa's chief minister in March 2000, Dalit labourer Ganapati Naik, now 42, had been living a happy if impoverished life with his bride and parents in...
More »SEARCH RESULT
Govt introduces Biosecurity Authority Bill In Lok Sabha-Sanjeeb Mukherjee
-The Business Standard Bill would pave way for setting up of an authority to help control pests & diseases in plants and animals Agriculture Minister Sharad Pawar today introduced a bill in the Lok Sabha that would pave way for setting up of a National Biosecurity Authority, which would help in prevention, control, eradication and management of pests and diseases of plants and animals and unwanted organisms. The Bill which was being debated...
More »Budget 2013-14: Rs. 1,000 crore each for women, youth funds
-The Hindu "To the women of India - we have a collective responsibility to ensure the dignity and safety of women. Recent incidents have cast a long dark shadow on our credentials. As more women enter public spaces...there are more reports of violence against them. We stand in solidarity with our girl children. We pledge to everything possible to keep them swcure. A number of measures are in the works...
More »'436 killed in clinical trials last year'-Durgesh Nandan Jha
-The Times of India As many as 436 people died last year due to serious adverse events (SAE) during clinical trials. Investigations are now on to ascertain how many of the deaths were caused by drugs administered to the trial subjects. Union health minister Ghulam Nabi Azad said on Friday that deaths could be due to life-threatening diseases such as cancer, heart failure and stroke or side-effects of the drugs or their...
More »Setback in TB war
-The Hindu The efforts to win the war against tuberculosis using an efficacious vaccine candidate (MVA85A) in infants aged 4-6 months have returned a disappointing verdict despite showing great promise in pre-clinical trials. Though it fulfilled the primary objective of safety and despite inducing modest immune responses, the efficacy of the vaccine was just 17.3 per cent, and hence considered insufficient to protect the infants against TB, notes a paper published...
More »